ArticleBMC infectious diseases2026
Antimicrobial resistance and toxin profiles of enterotoxigenic Escherichia coli in children under five years old with diarrhoea in Ouagadougou, Burkina Faso: a sentinel surveillance study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnterotoxigenic Escherichia coli (ETEC) remains a major cause of paediatric diarrhoeal disease in sub-Saharan Africa. Increasing antimicrobial resistance (AMR) threatens the effectiveness of empirical treatment, yet data on ETEC-specific resistance patterns and toxin profiles in Burkina Faso are scarce. This study assessed the prevalence, toxin gene distribution, and antimicrobial susceptibility of ETEC among children with acute diarrhoea in Ouagadougou, Burkina Faso.
methodsA hospital-based cross-sectional sentinel surveillance study was conducted at the "Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle (CHUP-CDG)", Ouagadougou, from May 2023 to April 2024. Stool samples were collected from 383 children under five years of age presenting with acute diarrhoea. ETEC was identified by culture followed by multiplex PCR targeting eltB (LT), estA1 (STp), and estA2 (STh) genes. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method and interpreted according to EUCAST 2023 criteria. Multidrug resistance (MDR) was defined as non-susceptibility to at least one agent in three or more antimicrobial classes.
resultsETEC was detected in 16 of 383 children, yielding a prevalence of 4.2% (95% CI: 2.4-6.7). The highest proportion of cases occurred in children aged 12-23 months (43.8% (7/16)). LT-producing strains predominated (50.0% (8/16)), followed by STp-producing strains (43.8%), with one LT + STh isolate (6.3% (1/16)). Antimicrobial resistance was high to commonly used oral agents, including trimethoprim (93.3% (14/15)), sulfamethoxazole (73.3% (11/15)), and ampicillin (66.7% (10/15)). Resistance to third-generation cephalosporins was substantial (ceftazidime 57.1% (8/14), cefotaxime 53.3% (8/15)), and fluoroquinolone resistance reached 40.0% (6/15) for ciprofloxacin. Eleven of 15 tested isolates (73.3% (7/15)) were classified as multidrug-resistant. All isolates remained susceptible to carbapenems and cefoxitin. While 80.0% (12/15) of isolates exhibited a phenotypic profile suggestive of extended-spectrum beta-lactamase (ESBL) production, only one isolate 6.7% (1/15) was phenotypically confirmed as an extended-spectrum beta-lactamase (ESBL) producer by double-disk synergy testing.
conclusionThe high prevalence of in vitro antimicrobial resistance among ETEC isolates suggests that the effectiveness of commonly used oral antibiotics as empirical treatment options in this setting may be compromised. The 73% MDR prevalence and ESBL production necessitate urgent antimicrobial stewardship implementation, enhanced surveillance systems, and accelerated ETEC vaccine development for this vulnerable population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.